Cemil EKİNCİ, Muhsin KAYA, Kadir BAHAR, Yasemin GENÇ, Işın SOYUER

Diagnostic value of Ki-67LI in hepatocellular carcinoma; Ki-67 antigen expression in hepatocellular carcinoma, metastatic adenocarcinoma and normal hepatocytes

One hundred liver fine-needle aspiration cytology (FNAC) specimens obtained from 42 patients with hepatocellular carcinomas (HCC), 38 patients with metastatic adenocarcinomas (MAC) and 20 patients with non-malignant liver disease (control group) were studied. Liver specimens were stained with an immunoperoxidase method using a monoclonal antibody to Ki-67 (MIB1). Ki-67 antigen was visualised in cold acetone, and a fresh liver needle aspiration cytology specimen using antibodies was used to identify proliferating hepatocytes. In this study it was examined that; if there is a difference between the groups in terms of Ki-67 positivity and degree of differentiation of tumor and the relationship there in. The Ki-67 labeling index (LI) of HCC cases was significantly different from the other two groups (p < 0.01). In additions, the numbers of hepatocytes positive for Ki-67 has a good correlation with the degree of differentiation of HCC (t = 2.96, p < 0.01).

PDF

___

1. Ouchi K, Sugawara T, Ono H, Fujiya T, et al. Mitotic index is the best predictive factor for survival of patients with resected hepatocellular carcinoma. Dig Surg 17(1):42-8, 2000
2. Suehiro T, Marsumata T, Itaska H et al: Clinicopathologic features and prognosis of resected hepatocellular carcinomas of varied sizes with special reference to proliferating cell nuclear antigen. Cancer 76: 399-405, 1995
3. Chapel F, Guettier C, Chastang C et al. Cancer 77: 864-871, 1996
4. Ojanguren I, ArÝza A, Llatjos M et al: Proliferating cell nuclear antigen expression in normal, regenerative and neoplastic liver. Hum Pathol 24: 905- 908,1993
5. Hino N, Higashi T, Nouso K et al: Proliferating cell nuclear antigen and Grade of malignancy in small hepatocellular carcinoma - Evaluation in US guided specimens-Hepatogastroenterology 44: 245-250, 1997
6. Souni Y, Virkajarvi N, Lehto VP et al: Hepatocellular carcinomas with a high proliferation index and a low degree of apoptosis and necrosis are associated with a shorthened survival. Br J Cancer 73: 1025-1030, 1996
7. Kitamoto M, Nakanishi T, Kira S et al: The assessment of proliferating cell nuclear antigen immunohistochemical staining in small hepatocellular carcinoma and its relationship to histologic characteristics and prognosis. Cancer 72: 1859-1865, 1993
8. Soulier JP, Gozin D, LeFrere JJ: A new method to assay des-d- carboxyprothrombin: Result obtained in 75 cases of hepatocellular carcinoma. Gastroenterology 91: 125-1262, 1986
9. Ojanguren I, Jastella E, Lladjos M et al: p53 immunoreaction in hapatocellular carcinoma and its relationship to etiologic factors. Acta Cytol 40: 1148- 1153, 1996
10. Farinati F, Cardin R, Derrico A et al: Hepatocyte proliferative activity in chronic liver damage as assessed by the monoclonal antibody MIB1 Ki-67 in archival material: the role of etiology, disease activity, iron and lipid peroxidation. Hepatology 23: 1468- 1475, 1996
11. Ng IOL, Ng M, Fan ST: Better survival in women with resected hepatocellular carcinoma is not related to tumor proliferation or expression of hormone receptors. The Am J Gastroenterol 92: 1355-1358, 1997
12. Kaita KD, Pettigrew N, Minuk GY: Hepatic regeneration in humans with various liver disease as assessed by Ki- 67 staining of formalin-fixed paraffin embedded liver tissues. Liver 17:13-16, 1997
13. Tiniakos DG, Brunt EM Proliferating cell nuclear antigen and Ki-67 lebeling in hepatocellular nodules: a comparative study. Liver 19 (1): 58-68, 1999
14. King KI, Hwang JJ, Chau Gy et al. Ki-67 expression as a prognostic marker in patients with hepatocellular carcinoma. J Gastrenterol Hepatol 13(3):273-9, 1998
15. Adachi E, Hashimoto H, Tsuneyoshi M: proliferating nuclear antigen in hepatocellular carcinoma and small cell liver dysplasia. Cancer 72: 2902-2909, 1993
16. Brown DC, Gatter KC: Monoclonal antibody Ki-67: its use in histopathology. Histopathology 17: 489-503, 1990
17. Gerdes J, Schwab U, Lemke H et al: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31: 13-20, 1983
18. Ming CW, Chao WM, Zhang XH: Primary hepatocellular carcinoma in women of mainland China. Cancer 71: 2941-2945, 1993
19. Shar S, Kew MC. Oral contraceptives and hepatocellular carcinoma. Cancer 49: 407-410, 1982
20. Coe JE, Ishak KG, Ross MJ: Estrogen induction of hepatocellular carcinoma in Armenian hamsters. Hepatology 11: 570-577, 1990
21. Tan CK, Chow PK, Findlay M, Wong C, Machin D. Use of tamoxifen in hepatocellular carcinoma: a review and paradigm. J Gastrenterol Hepatol 15(7): 725-729, 2000
22. Liu CL, Fan ST, Ng IO, Lo CM, Poon RT, Wong J. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. Am J Gastroenterol 1995(1):218-22, 2000.
23. The Liver Cancer Study Group of Japan. Predictive factors for long-term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 74: 2772-2780, 1994.